Regentis Biomaterials reported a net loss of $2.6 million, or $0.44 per share, for the six months ended June 30, 2026, compared to a $3.2 million loss in the prior year period. The company completed a private placement in June 2026 raising approximately $6.5 million and held cash reserves of $9.0 million as of June 30, 2026. Clinical progress includes treating 43 of 80 patients in its U.S. pivotal GelrinC trial, with enrollment completion expected by year-end 2026. The company also received regulatory approval for a new manufacturing process that increases production yield by 400% and expanded its European commercialization network. Regentis Biomaterials Ltd is a regenerative medicine company focused on developing innovative tissue repair solutions using hydrogel implants.
